SCHEMBL2373869

SCHEMBL2373869

CCCn1ncc(Cl)c1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.44
POLB P06746 3/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPC1 O15118 3/20 0.39
RAB9A P51151 2/20 0.39
HTT P42858 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MITF O75030 2/20 0.39
ALDH1A1 P00352 2/20 0.39
PKM P14618 1/20 0.39
LMNA P02545 2/20 0.38
BLM P54132 1/20 0.38
HCAR3 P49019 1/20 0.37
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2373014 0.90 KMT2A (0.45) L3MBTL1POLBKMT2ATSHRMAPK1
SCHEMBL1431393 0.86 POLB (0.56) POLBKMT2ATSHRMAPK1TDP1
SCHEMBL15768068 0.80 POLB (0.42) L3MBTL1POLBKMT2ATSHRMAPK1
SCHEMBL2373056 0.78 KMO (0.40) POLBKMT2ATSHRMAPK1TDP1
SCHEMBL1431321 0.76 HTT (0.53) KMT2ARAB9AHTTSMN1; SMN2ALDH1A1
SCHEMBL15768031 0.76 L3MBTL1 (0.37) L3MBTL1POLBKMT2ATSHRMAPK1
SCHEMBL13578041 0.71 POLB (0.56) POLBKMT2ATSHRMAPK1TDP1
SCHEMBL1431846 0.71 POLB (0.56) POLBKMT2ATSHRMAPK1TDP1
SCHEMBL9234092 0.71 HTT (0.57) L3MBTL1POLBKMT2AMAPK1NPC1
SCHEMBL15650467 0.70 POLB (0.55) POLBKMT2ATSHRMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2552918-B1 N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS HOFFMANN LA ROCHE (CH) 2014-06-11 EP claimed
US-8410117-B2 Imidazopyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2013-04-02 US claimed
EP-2552918-A1 N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS F. Hoffmann-La Roche AG (CH) 2013-02-06 EP claimed
EP-2552918-B1 N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS HOFFMANN LA ROCHE (CH) 2014-06-11 EP disclosed
US-8410117-B2 Imidazopyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2013-04-02 US disclosed
EP-2552918-A1 N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS F. Hoffmann-La Roche AG (CH) 2013-02-06 EP disclosed
US-20110237564-A1 IMIDAZOPYRIMIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2011-09-29 US disclosed
WO-2011117264-A1 N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237564-A1 IMIDAZOPYRIMIDINE DERIVATIVES PDE5A, PDE3B, PDE3A L3MBTL1 4145/4885POLB 2003/4885KMT2A 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.